PO-0735: SBRT is safe and effective in low- intermediate risk prostate cancer. Results of a phase II study
D'Agostino, G.R., Villa, E., Piergallini, L., Franzese, C., Clerici, E., Tozzi, A., Iftode, C., Comito, T., Navarria, P., De Rose, F., Ascolese, A.M., Mancosu, P., Scorsetti, M.Volume:
115
Language:
english
Journal:
Radiotherapy and Oncology
DOI:
10.1016/s0167-8140(15)40727-3
Date:
April, 2015
File:
PDF, 90 KB
english, 2015